A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
- 05 Septembre 2024 - 1 mn de lecture
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.
05 Septembre 2024
1 mn de lecture
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
05 Septembre 2024
1 mn de lecture
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
05 Septembre 2024
1 mn de lecture
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
05 Septembre 2024
1 mn de lecture
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
05 Septembre 2024
1 mn de lecture
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
05 Septembre 2024
1 mn de lecture
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
05 Septembre 2024
1 mn de lecture
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
05 Septembre 2024
1 mn de lecture
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
05 Septembre 2024
1 mn de lecture
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
05 Septembre 2024
1 mn de lecture